Libourel et al identified risk factors for arterial or venous thrombosis in a patient with acute myeloid leukemia (AML) undergoing induction chemotherapy. These can help to identify a patient who may benefit from more aggressive management. The authors are from Sint Franciscus Gashuis, VU Medical Center, and Erasmus MC in Rotterdam, The Netherlands.